TNBC accounts for approximately 15% of breast cancers and is associated with a higher risk of relapse and a worse overall survival compared with other breast cancer subtypes, including ER-positive (luminal) and HER2-positive (HER2 over-expression) subtypes [3]. Here, ESR1 is linked to breast carcinoma.